跳到正文
原文
Endpoints News 生物医药· Kyle LaHucik·· 2026-10-09AI 评分43

Viatris将以16.5亿美元现金收购Pacira BioSciences,加码非阿片类疼痛药物

Viatris to make $1.65B Pacira acquisition, adding to momentum in pain

AI 导读

仿制药与品牌药生产商Viatris将以16.5亿美元现金收购商业化阶段的Pacira BioSciences,由此进入非阿片类疼痛药物领域。交易于周四上午宣布。

正文

Vi­a­tris, a gener­ics and brand­ed med­i­cines mak­er, is buy­ing in­to non-opi­oid pain drugs with a cash ac­qui­si­tion of com­mer­cial-stage Paci­ra Bio­Sciences.

The Thurs­day morn­ing deal …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

来源:Endpoints News 生物医药 · endpoints.news